Study S001253

A 24-week, Multicenter, International, Randomized (1:1), Parallel-group, Open-label, Comparative Study of Insulin Glargine Versus Liraglutide in Insulin-naïve Patients With Type 2 Diabetes Treated With Oral Agents and Not Adequately Controlled, Followed by a 24-week Extension Period With Insulin Glargine for Patients Not Adequately Controlled With Liraglutide

ClinicalTrials.gov record

Registration

Registration: NCT01117350
Acronym: EAGLE
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE4
Masking: NONE
Status: COMPLETED
Enrollment: 978
Start: 2010-07
Primary completion: 2012-10
Lead sponsor: Sanofi
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Insulin glargine; DRUG:Liraglutide; DRUG:Metformin
Results posted: TRUE
Secondary identifiers: EUDRACT_NUMBER:2010-018437-21; OTHER:U1111-1116-9684

Registered primary outcomes

Percentage of Patients Whose Glycosylated Haemoglobin (HbA1c) <7% at the End of the Comparative Period [week 12, week 24]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.